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In 2009, the Food and Drug Administration discovered that individuals taking over-thecounter pain medications containing acetaminophen were at risk of unintentional overdose
because these patients would supplement the painkillers with other medications containing
acetaminophen. This resulted in an increase in liver failures and death over the years. To
combat this problem, the FDA decided to lower the dosage from 1000 mg to 650 mg every four
hours, thus reducing this risk (U.S. Food and Drug Administration). The measures taken in this
example demonstrate the concepts behind the field of Pharmacology. Pharmacology is known
as the study of the uses, effects, and mode of action of drugs (“Definition of Pharmacology”).
Knowledge of drug concentrations is of extreme importance when determining the dosage and
frequency in which patients are administered medication. By ascertaining how much time is
required to eliminate a drug, pharmacists are able to decide when the next dosage should be
administered. By diving into this field, we are able to answer questions such as “how much
intravenous fluid should be administered to each individual patient?” or “Why should Tylenol
only be taken every 4 hours?”. Specifically, the concepts within pharmacokinetics and
pharmacodynamics aim to explain these answers using specific mathematical systems.
To begin, we must first understand the basic principles of pharmacokinetics. According
to the 2011 Nurse’s Drug Handbook, pharmacokinetics is a branch of Pharmacology. It is
currently defined as the study of a drug’s actions as it passes through the body during
absorption, distribution, metabolism, and excretion (2). These four parts all play a significant
role in the movement of drugs in the human system. Absorption implies the medication is able
to be biologically passed through a bi-lipid cell membrane either actively or passively. The drug
can enter via three methods of administration, with enteral (oral), parenteral (intravenous), or
transcutaneous (topical) drugs. Distribution is the process of the drug being transferred to
other regions of the body, or action sites, by bodily fluids such as one’s plasm. The conversion

of the drug into useful molecules and compounds is known as metabolism and occurs mainly in
the liver, or hepatic system. Finally, excretion is the elimination of the drug from the body,
usually taking place in the kidneys, or renal system (2011 Nurse’s Drug Handbook 4).
Furthermore, clinical pharmacokinetics is the application of pharmacokinetic principles
to the safe and effective therapeutic management of drugs in an individual patient (Spruill et al.
1). Though it is not possible to directly access the sites where the drug becomes effective, such
as in human organs, we are able to successfully measure the concentration of a drug at any
given time via the blood, saliva, or urine. Concentration is defined as the amount of the drug
divided by the volume where the drug is distributed (Spruill et al. 10). This is very useful when
determining how a drug is distributed throughout a person’s plasma. A large volume of
distribution indicates the drug dosage has been distributed fully into the body fluids (Spruill et
al. 11). The volume of distribution varies considerably between patients given the fact that
genetic differences as well as illnesses can affect the plasma concentration within that body.
Thus, patients with a lower plasma concentration amount would require a lower dosage of a
drug to achieve a full distribution throughout the body; something important to note when
servicing patients hemorrhaging while receiving medication. The concentration used to
calculate the volume distribution is constantly changing as well due to excretion (Spruill et al.
11). Therefore, concentration of the drug in the bloodstream is directly proportional to the
concentration in the tissue; higher doses of the drug implies a higher dose in the bloodstream
and therefore higher dose diffused into the tissue.
Pharmacodynamics refers to the relationship between drug concentration at the site of
action and the resulting effect, including the time course and intensity of therapeutic and
adverse effects (2011 Nurse’s Drug Handbook 5). There are a few variables that influence the
relationship. Time course is one of the variables defined as the length of time a drug stays at
the receptor site which in turn determines the length of its effect. Another is tolerance, which
states an increased concentration over time at a receptor site can actually cause the drug’s

effectiveness to decrease. As demonstrated in the graph to the left, when the number of doses
increases, the drug concentration must also increase to get the same desired effect because the
human body develops a resistance to
the drug (Spruill et al. 3). Human
bodies increase its metabolism so a
drug is excreted from the body quicker
and its time in the body decreases.
Conversely, bacteria have internal
survival responses that allow the
bacteria to create protective barriers
that provide a resistance to certain
drugs the more it is exposed. This is
why the long term use of non-steroidal anti-inflammatory drugs, such as ibeprophen, and
repeated use of antibiotics may actually be detrimental to the human body.
The ways in which drugs are received by the body differ by the type of drug and the
drug’s mode of action. For example, a medication that aids in lowering blood pressure will
target the autorhythmic cells in the human heart to block the release of calcium, thereby
slowing contractions in the heart and lowering mean arterial pressure. But an antibiotic like
penicillin, that targets foreign bacteria in the body, will attach to the bacterial cell, preventing
the cell from forming a protective cell wall and causing it to die. Each drug has different
mechanisms because receptor sites vary (Spruill et al. 2). As a result, the concentration at the
receptor site must vary accordingly, proving the importance of understanding these biological
processes.
Given this knowledge of pharmacokinetics and pharmacodynamics, we can now look
into some mathematical systems. We will soon be able to predict the amount of drugs in the
bloodstream, and therefore tissue, at any given time and determine the rate at which it is
leaving. This is achieved through compartment models (Spruill et al. 8). The compartments in a
given model represent the locations where the drug travels throughout the body, for instance,

the blood stream, and organ tissues, or urine. The simplest form is the one-compartment
model and is in fact a first order model.
In this instance, the drug is administered
into the body, enters the plasma, and is excreted
from the compartment. This can also be looked at
in mathematical terms. There is the initial amount
of the dosage, the compartment, which is the
concentration of the drug in the body, and the movement out is the rate at which the drug is
leaving, or the rate of change. Since this rate is decreasing exponentially, we can utilize the
exponential decay function to determine the amount of the drug at any given time. The rate of
change in the concentration is proportional to the current concentration so we start off with
the equation

𝑑𝑃
𝑑𝑡

= 𝑃𝑘 where k is the growth rate, P is the current amount, and dP/dt is the rate

of change. This equation is separable so

1
𝑃

𝑑𝑃 = 𝑘𝑑𝑡

1

 ∫ 𝑃 𝑑𝑃 = ∫ 𝑘𝑑𝑡
 𝑙𝑛|𝑃| = 𝑘𝑡 + 𝐶
 𝑃 = 𝑒 𝑘𝑡+𝐶 = 𝑒 𝑘𝑡 𝑒 𝑐
 𝑃 = 𝑃𝑜 𝑒 𝑘𝑡
According to Calculus: Single Variable, “Every solution to the equation dP/dt = kP can be
written in the form P = Poekt, where Po is the value of P at t = 0, and k>0 represents growth,
whereas k <0 represents decay”(Gleason, Hughes-Hallett, McCallum 13). By utilizing this
equation, we can solve real life applications. For instance, “The rate at which a drug leaves the
bloodstream and passes into the urine is proportional to the quantity of the drug in the blood
at that time. If an initial dose of Qo is injected directly into the blood, 20% is left in the blood
after 3 hours. Write an equation and solve for the quantity Q of the drug in the blood after t
hours” (Gleason, Hughes-Hallett, McCallum 618). Since 20% is left, we know 𝑄𝑜 = 1 and
𝑄(3) = 0.2 so we can use our decay function 𝑄 = 𝑄𝑜 𝑒 𝑘𝑡 and solve for k. Therefore, we can
plug

0.2 = 𝑒 𝑘3
 𝑙𝑛|0.2| = 𝑘3
 k= -.536479
 𝑄 = 𝑄𝑜 𝑒 −0.536479𝑡
Additionally if we plug in a time value and initial dosage amount, we can determine how much
of a drug is in a patient’s body at that time.
Also, “The half-life of an exponentially decaying quantity is the time required for half of
it to decay” (Gleason, Hughes-Hallett, McCallum 14). It correlates with the duration of action in
the hepatic and renal systems. The longer the half-life, the less often the drug needs to be
administered and the longer it remains in the body (Spruill et al. 33). Half-life is useful in the
medical field for two reasons: it reveals how long it takes for the body to completely eliminate
the drug from the body as well as how frequent the doses should be given out (Gordon).
Within the biological setting, it takes 4.5 half-lives for a drug to be 95% eliminated so by
multiplying the half-life time by 4.5, the time span before the next dosage is revealed (Gordon).
After being introduced to the concept of one compartment models, we can now dive
into two compartment models. This is a situation in which the drug passes through two
separate locations within the body including the blood, organs and tissues, or urine. This
effects the amount of the drug in the body because now it is being metabolized in two places at
different rates. The right
hand picture
demonstrates this
process and gives us the
following system of
equations to model it accordingly (Koch-Noble 237).

dg
dt
db
dt

= 𝑓(𝑡) − βg(t).
= βg(t) − αb(t).

In this instance,
𝑓(𝑡)= initial dosage of ingestion at time 0
𝑏(𝑡)= amount of drug in the bloodstream at time t
𝑔(𝑡)= amount of drug in the gastrointestinal tract (GI tract) at time t
𝛼, 𝛽= the metabolism of the drug in the bloodstream and GI tract, respectively
This is a non-homogeneous equation because 𝑓(𝑡) does not play a direct role on the other
functions. So to solve, we want to turn the system into a second order linear equation.
Generally, a second order linear equation is written in the form of 𝐴𝑦 ′′ + 𝐵𝑦 ′ + 𝐶𝑦 = 0. To
solve, let 𝑦 = 𝑒 𝑟𝑡 and insert into the general formula.
⟹ 𝑟 2 𝑒 𝑟𝑡 + 𝑟𝑒 𝑟𝑡 + 𝑒 𝑟𝑡 = 0
⟹ 𝑟2 + 𝑟 + 1 = 0
This last equation is the characteristic equation which we will utilize later. When the quadratic
is solved, if we get distinct real roots for 𝑟, the general solution for a homogeneous equation is
𝑦ℎ = 𝐶1 𝑒 −𝑟1 𝑡 + 𝐶2 𝑒 −𝑟2 𝑡 .
Furthermore, the solution to a non-homogeneous equation is 𝑦 = 𝑦ℎ + 𝑦𝑝 where p is the
particular solution. We can use this to solve our system modeling the two compartments. We
start with the system,
dg
dt
db
dt

= 𝑓(𝑡) − βg(t).
= βg(t) − αb(t).

We rewrite these equations to factor out g(t),
[D + β][g(t)] = 1
−𝛽[g(t)] + [D + α][b(t)] = 0
(Note D represents derivative in terms of t and 𝑓(𝑡) = 1)

We want the g(t) terms to have the same “coefficients” to solve by elimination so we multiply
the top equation by 𝐷 + β and the bottom equation by 𝛽,
𝛽[D + β][g(t)] = 𝛽
[D + β](−𝛽[g(t)] + [D + α][b(t)]) = 0
Adding the two equations will eliminate the g(t) terms and give us,
⇒ [D + β][D + α][b(t)] = 𝛽
When we foil, we get
⇒ 𝑏 ′′ + (𝛽 + 𝛼)𝑏 ′ + 𝛽𝛼𝑏 = 𝛽
Now we use the characteristic equation discussed earlier,
⇒ 𝑟 2 + (𝛽 + 𝛼)𝑟 + 𝛽𝛼 = 0
⟹ (𝑟 + 𝛽)(𝑟 + 𝛼) = 0 so 𝑟 = −𝛽 𝑎𝑛𝑑 − 𝛼
The homogeneous solution is then,
𝑏ℎ = 𝐴𝑒 −𝛼𝑡 + 𝐵𝑒 −𝛽𝑡
We must also consider the particular solution since this system is non-homogeneous. To do so,
we let the particular solution be represented by a variable,
𝑏 ′′ + (𝛽 + 𝛼)𝑏 ′ + 𝛽𝛼𝑏 = 𝛽
𝐿𝑒𝑡 𝑏𝑝 = 𝐾
We plug this in and get,
𝛽𝛼𝐾 = 𝛽
⟹𝐾=

1
𝛼

So our complete equation is,
𝑏(𝑡) = 𝐴𝑒 −𝛼𝑡 + 𝐵𝑒 −𝛽𝑡 +

1
𝛼

Here 𝑏(𝑡) is the amount of drugs in the bloodstream in terms of time, 𝑡. 𝐴 and 𝐵 are the drug
amounts of the first and second compartment, respectively. 𝛼 and 𝛽 are the decay rate
constants for each compartment(Spruill et al. 78). Using this model, we can determine the
amount of the drug in the blood at any given time when the drug passes into two
compartments.
In this final portion on the paper, we will look at how multiple injections can be
modelled over time by using ordinary differential equations (ODEs). In these cases, a patient
would be receiving drug doses at regular intervals and between each injection, the drug would
be metabolized. This creates a model in which a discrete function is a part of a continuous
function (Koch-Noble 235). We can start off with the equation,
db
= 𝑓(𝑡) − αb(t)
dt
𝑏(𝑡)= amount of drug in the bloodstream at time t
𝑓(𝑡)= dosing pattern of injections at time t (This is a discrete value since dosages will remain
constant)
α = metabolism of the drug
It is interesting to note in the absence of another injection, or when 𝑓(𝑡)= 0, the model will
function just as the exponential decay function examined earlier in this paper. In this case, the
drug will be fully excreted from the bloodstream as expected. However, the constant injections
force the concentration of the drug to spike back up to the initial value and the decay cycle
restarts.
The given ODE indicates that the rate at which the amount of a drug in the bloodstream is
changing over a period of time (continuous) while injections of the drug are being administered
(discrete). We want to transform this into a function that will tell us the amount of the drug in
the bloodstream at any given time. To do so, we will utilize the Laplace transform.
First, we will look at the basic properties of three elements needed to solve the equation:
the Laplace transform, step function, and Dirac delta function. The Laplace transform of a
function is a way to evaluate ODE’s in a simpler manner. It is defined as

∞

ℒ{𝑓(𝑡)} = ∫0 𝑒 −𝑠𝑡 𝑓(𝑡)𝑑𝑡
so long as the integral converges and 𝑓(𝑡) doesn’t grow larger than the exponential. Then when
the integral is evaluated, we get a new function F(s). Thus,
ℒ{𝑓(𝑡)} = 𝐹(𝑠) where s is similar to a frequency space
This model also utilizes the step function, designated by 𝑢(𝑡). The definition of the step
function states that,
0,
𝑢(𝑡) = {
1,

𝑡 <0
𝑡>0

This essentially means that when t is equivalent to 𝑎𝑛 we get a value of 1 and the function is
turned on. Practically speaking, this means if the time when the drug amount is measured is
the same as the time when the drug is injected, we will get a value. It is also important to note
that the derivative of the step function is the delta function,
𝑑
𝑢(𝑡) = 𝛿(𝑡)
𝑑𝑡
The Dirac delta function is defined as a linear functional from a space of test functions
𝑓 . The action of 𝛿 on 𝑓 gives the value at 0 of 𝑓 for any function 𝑓(“Dirac Delta Function”). By
definition,
∞

∫ 𝑔(𝑡)𝛿(𝑡 − 𝑎)𝑑𝑡 = 𝑔(𝑎)
−∞

Identities include,
0,
𝛿(𝑡) = {
∞,

𝑡 ≠0
𝑡=0

∞

∫−∞ 𝛿(𝑡)𝑑𝑡 = 1.

When time is not equal to 0 the resulting value is 0, but when t = 0, or any time a, the impulse
occurs and we get a value. Whenever we have 𝛿(𝑡 − 𝑎), we have an impulse shift to time a,
but the area is still 1 (“Dirac Delta Function”).

0,
𝛿(𝑡 − 𝑎) = {
"∞",

𝑡 ≠𝑎
𝑡=𝑎

Since 𝑓(𝑡) is defined as the discrete pulse function, it is actually a delta function. So,
𝑓(𝑡) = 𝛿(𝑡 − 𝑎1 ) + 𝛿(𝑡 − 𝑎2 ) + ⋯ + 𝛿(𝑡 − 𝑎𝑛 )
where 𝑎𝑛 is the time when dosage number, n, is administered.

With those in mind, we can solve the ODE. We start off with the equation,
db
dt

= 𝑓(𝑡) − αb(t).

We can utilize the Laplace transform to solve this ODE. So we take the Laplace transform of the
left and right hand side of our equation.
db

ℒ { dt } = ℒ{𝑓(𝑡) − αb(t)}.
Linearity properties allow us to take the Laplace transform on both sides, from each component
on the right hand side, and factor out α as a constant,
db

ℒ { dt } = ℒ{𝑓(𝑡)} − αℒ{b(t)}.
To evaluate, we can look at each side separately. When looking at a table of Laplace transforms
db

(Dawkins), we can use the Laplace transform definition to solve ℒ { dt } ,
∞
db
db
ℒ { } = ∫ 𝑒 −𝑠𝑡 𝑑𝑡
dt
dt
0

We solve this by using integration by parts which says ∫ 𝑢𝑣 ′ = 𝑢𝑣 − ∫ 𝑣𝑢′, so we can assign 𝑢
and 𝑣 ′ to parts of our integral and evaluate,
𝑢 = 𝑒 −𝑠𝑡
𝑢′ = −𝑠𝑒 −𝑠𝑡 𝑑𝑡
⇒ 𝑒 −𝑠𝑡 𝑏(𝑡)|𝑡=∞
𝑡=0

𝑣′ =

db
𝑑𝑡
dt

𝑣 = 𝑏(𝑡)
∞

+ ∫0 𝑠𝑒 −𝑠𝑡 𝑏(𝑡)𝑑𝑡

⇒ −𝑏(0) + 𝑠 ⋅ 𝐵
Therefore we get number 35 on our Laplace transform table,

𝑠 ⋅ 𝐵 − 𝑏(0)
where 𝐵 is our new function and 𝑏(0) is our initial amount of the drug.

We then use the Laplace transform for both functions on the right hand side, utilizing the table
once again (Dawkins).
ℒ{𝑓(𝑡)} − αℒ{b(t)}.
⇒ ℒ{𝛿(𝑡 − 𝑎1 ) + 𝛿(𝑡 − 𝑎2 ) + ⋯ + 𝛿(𝑡 − 𝑎𝑛 )} − αℒ{b(t)}.
When we take the Laplace transform of the delta function, the definition of the Laplace
transform gives us the solutions through a simple substitution of variables,
∞

ℒ{𝛿(𝑡 − 𝑎)} = ∫ 𝑒 −𝑠𝑡 𝛿(𝑡 − 𝑎)𝑑𝑡 = 𝑒 −𝑎𝑠
0

So our right hand side solution turns out to be,
⇒ (𝑒 −𝑎1 𝑠 + 𝑒 −𝑎2 𝑠 + ⋯ + 𝑒 −𝑎𝑛𝑠 ) − α ⋅ 𝐵 (by 26 and the definition)
Finally, both sides are combined and algebra is used to rearrange the terms so the 𝐵
terms are on the left and the 𝑠 terms are on the right.
𝑠 ⋅ 𝐵 − 𝑏(0) = (𝑒 −𝑎1 𝑠 + 𝑒 −𝑎2 𝑠 + ⋯ + 𝑒 −𝑎𝑛𝑠 ) − α ⋅ 𝐵
⟹ 𝑠 ⋅ 𝐵 + α ⋅ 𝐵 = (𝑒 −𝑎1 𝑠 + 𝑒 −𝑎2 𝑠 + ⋯ + 𝑒 −𝑎𝑛𝑠 ) + 𝑏(0)
⟹ 𝐵(𝑠 + α) = (𝑒 −𝑎1 𝑠 + 𝑒 −𝑎2 𝑠 + ⋯ + 𝑒 −𝑎𝑛𝑠 ) + 𝑏(0)
⟹𝐵 =

( 𝑒 −𝑎1 𝑠 + 𝑒 −𝑎2 𝑠 +⋯+ 𝑒 −𝑎𝑛 𝑠 )+𝑏(0)
(𝑠+α)

Now we use the inverse Laplace transform to convert our equation for B back into b(t), applying
the inverse transform it to each component.
𝑏(0)

𝑒 −𝑎1 𝑠

𝑒 −𝑎2 𝑠

𝑒 −𝑎𝑛 𝑠

ℒ −1 {𝐵} = ℒ −1 {(𝑠+α)} + ℒ −1 {(𝑠+α)} + ℒ −1 {(𝑠+α)} + ⋯ + ℒ −1 { (𝑠+α) }

Note,
𝑒 −𝑎𝑛 𝑠

1

ℒ −1 { (𝑠+α) } = ℒ −1 {𝑒 −𝑎𝑛𝑠 ⋅ 𝐹} where 𝐹 = (𝑠+α)
1

There are four steps to solve. First, identify 𝐹 which we set equal to (𝑠+α). Then we take the
inverse Laplace transform of 𝐹 to get 𝑓(𝑡) by the definition. After, we replace 𝑡 with 𝑡 − 𝑎𝑛
and finish by multiplying 𝑓(𝑡) by the step function. We can do this because as stated earlier,
the derivative of the step function is the delta function. After doing so, we get,
ℒ −1 {𝑒 −𝑎𝑛𝑠 ⋅ 𝐹} = 𝑓(𝑡 − 𝑎𝑛 ) ∙ 𝑢(𝑡 − 𝑎𝑛 ) (27)
We use the Laplace transform table again and plug in
𝑓(𝑡) = 𝑒 −∝𝑡 (2)
Once this is done for every component, we get the final equation,
𝑏(𝑡) = 𝑏(0)𝑒 −∝𝑡 + 𝑢(𝑡 − 𝑎1 )𝑒 −∝(𝑡−𝑎1 ) + 𝑢(𝑡 − 𝑎2 )𝑒 −∝(𝑡−𝑎2 ) + ⋯ + 𝑢(𝑡 − 𝑎𝑛 )𝑒 −∝(𝑡−𝑎𝑛)
With the use of this equation, we can now determine the amount of the drug in the
body at time, t. As time goes on, more of the function is turned on and the result is a
temporary spike in the concentration. This spike cannot increase much though because the
exponential decay function is attached to it, causing a decrease in the drug concentration.
When 𝑏(𝑡) is graphed, the result is exactly as we would expect.

In this graph, the bottom of the curve is when the drug reaches its minimum effective
concentration, the peak is its minimum toxic concentration, and the whole curve is the

therapeutic window which is the range in which the drug is working effectively (Koch-Noble
238). As discussed previously, every individual drug has its own chemical properties and are
effected by factors in the body differently. For some drugs, it is preferable to give smaller doses
more frequently while with others it is preferable to give larger doses over longer time
intervals. Larger, less frequent doses cause the therapeutic range to be greater (longer time
from peak to pit). This can be a disadvantage because there is a greater chance of staying in
the toxic range or subtherapeutic range longer. Likewise, smaller, more frequent doses may not
be practical when it comes to administering (Spruill et al. 60).
To conclude, we have looked at just a few of the models that aid in modeling drug
injection types within the field of pharmacokinetics. While the complexity of each formula
varies, the result is the same; we are able to determine the amount of a drug within the body at
any given time. However, it is important to note there are multiple other factors that play a
role in this amount. One’s ability to metabolize a single drug fluctuates between patients.
Interactions between two or more medications may also influence the rate of decay. With an
insight into the workings of pharmacodynamics, these factors can be considered and may be
adjusted for in our mathematical interpretations. By generating these models, we can develop
a deeper understanding of how drugs operate in order to further the effectiveness of their
administration, thus accomplishing the ultimate goal of improving the patient’s well-being.
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